Lake Street Maintains LENSAR(LNSR.US) With Buy Rating, Maintains Target Price $8
LENSAR (LNSR) Gets a Buy From Lake Street
Lake Street Maintains LENSAR(LNSR.US) With Buy Rating, Maintains Target Price $8
Lake Street Maintains LENSAR(LNSR.US) With Buy Rating, Maintains Target Price $8
Lake Street Keeps Their Buy Rating on LENSAR (LNSR)
Lake Street Sticks to Its Buy Rating for LENSAR (LNSR)
LENSAR Analyst Ratings
Lake Street Initiates Coverage On LENSAR With Buy Rating, Announces Price Target of $8
BTIG Keeps Their Buy Rating on LENSAR (LNSR)
Buy Rating Recommended for Undervalued LENSAR Amid Strong Growth and Successful ALLY Launch
BTIG Keeps Their Buy Rating on LENSAR (LNSR)
LENSAR (LNSR) Gets a Buy From BTIG
BTIG Reaffirms Their Buy Rating on LENSAR (LNSR)
Analysts Offer Insights on Healthcare Companies: LENSAR (LNSR) and Cerevel Therapeutics Holdings (CERE)
No Data